Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What key factors are powering the surge in the nontuberculous mycobacterial infection market right now?
The nontuberculous mycobacterial infection market has grown steadily, with expectations to grow from $14.25 billion in 2024 to $15.11 billion in 2025 at a CAGR of 6.0%. Key growth drivers in previous years include improved diagnostics, an aging population, increased cystic fibrosis awareness, and greater use of immunosuppressive medications.
How fast Is the nontuberculous mycobacterial infection market expected to grow, and what’s its future value?
The nontuberculous mycobacterial infection market is expected to see steady expansion, reaching $19.57 billion in 2029 at a CAGR of 6.7%. Contributing factors include antimicrobial drug development, rising awareness, genetic research advancements, and telehealth adoption. Key trends involve personalized treatment approaches, regulatory focus, combination therapies, and digital health tools.
Get your nontuberculous mycobacterial infection market report here!
What are the leading drivers of growth in the nontuberculous mycobacterial infection market?
The rising air pollution levels are expected to propel the non-small cell lung cancer (NSCLC) market forward. Air pollution, which consists of harmful gases and particulate matter, negatively impacts human health and increases the risk of lung cancer by inducing inflammation, DNA damage, and mutations in lung cells. According to the World Health Organization in June 2023, air and household pollution contributed to 7 million premature deaths annually, with 2.4 billion people exposed to harmful levels of household pollution due to cooking methods involving kerosene, biomass, and coal. Additionally, a September 2022 World Bank report estimated that air pollution-related health damages amount to $8.1 trillion annually, representing 6.1% of global GDP. Consequently, the increasing air pollution levels are driving the growth of the NSCLC market.
What are the key segments defining the nontuberculous mycobacterial infection market?
The nontuberculous mycobacterial infection market covered in this report is segmented –
1) By Drug Class: Macrolides, Rifampin, Aminoglycoside, Other Drug Classes
2) By Route Of Administration: Oral, Parenteral, Other Routes
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Macrolides: Azithromycin, Clarithromycin
2) By Rifampin: Rifampin, Rifabutin
3) By Aminoglycoside: Amikacin, Streptomycin
4) By Other Drug Classes: Ethambutol, Clofazimine, Linezolid
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13020&type=smp
Who are the key players steering the development of the nontuberculous mycobacterial infection market?
Major companies operating in the nontuberculous mycobacterial infection market are Pfizer Inc., Johnson & Johnson, F. Hoffman La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol Myers Squibb, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceutical Company, Eli Lilly and Company, C.H. Boehringer Sohn AG & Co. KG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Astellas Pharma Inc., Vertex Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Horizon Therapeutics PLC, Lupin Limited, BioMarin Pharmaceutical Inc., Ionis Pharmaceuticals Inc., Insmed Incorporated, Paratek Pharmaceuticals Inc., Spero Therapeutics Inc., Aradigm Corporation, Dauntless Pharmaceuticals Inc., Validus Pharmaceuticals LLC.
What emerging trends are influencing the growth of the nontuberculous mycobacterial infection market?
Primary businesses in the nontuberculous mycobacterial infection market are embracing innovative treatment approval methods, including fast track designation for pharmaceutical approval, to maintain their market dominance. The FDA’s Fast Track designation is a procedure aimed at rapidly advancing the development and assessment of medications for serious health conditions that lack sufficient medical solutions. For example, the US-based federal entity, the Food and Drug Administration, awarded NUZYRA Fast Track Designation in July 2022 for treating (NTM) lung disease provoked by Mycobacterium avium complex (MAC). NUZYRA (omadacycline), a new broad-spectrum antibiotic, was created to fight against severe bacterial infections, including those brought about by resistant strains. This designation accelerates the development and review processes for the NUZYRA antibiotic to address significant unmet medical demands.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13020
Which regions are most influential in expanding the nontuberculous mycobacterial infection market?
North America was the largest region in the nontuberculous mycobacterial infection market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in nontuberculous mycobacterial infection market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Browse Through More Similar Reports By The Business Research Company:
Cough And Cold Preparations Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/cough-and-cold-preparations-global-market-report
Respiratory Disposables Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/respiratory-disposables-global-market-report
Respiratory Monitoring Devices Global Market Report 2024
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on: